408 related articles for article (PubMed ID: 3918536)
1. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
[TBL] [Abstract][Full Text] [Related]
3. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
4. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
Harris RH; Nichols R; Schmeling JW; Ramwell PW
Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
[No Abstract] [Full Text] [Related]
5. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
6. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
Hamid-Bloomfield S; Whittle BJ
Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
[TBL] [Abstract][Full Text] [Related]
8. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
Gresele P; Deckmyn H; Huybrechts E; Vermylen J
Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299
[TBL] [Abstract][Full Text] [Related]
9. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
10. Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides.
Di Minno G; Bertelé V; Cerletti C; de Gaetano G; Silver MJ
Thromb Res; 1982 Feb; 25(4):299-306. PubMed ID: 6803385
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane synthase inhibition causes re-direction of prostaglandin endoperoxides to prostaglandin D2 during collagen stimulated aggregation of human platelet rich plasma.
Orchard MA; Waddell KA; Lewis PJ; Blair IA
Thromb Res; 1985 Sep; 39(6):701-10. PubMed ID: 3936223
[TBL] [Abstract][Full Text] [Related]
12. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
Hornberger W; Patscheke H
Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
[TBL] [Abstract][Full Text] [Related]
13. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
Gresele P; Blockmans D; Deckmyn H; Vermylen J
J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
[TBL] [Abstract][Full Text] [Related]
14. Effects of OKY 1581 on bronchoconstrictor responses to arachidonic acid and PGH2.
Tilden SJ; Underwood DC; Cowen KH; Wegmann MJ; Graybar GB; Hyman AL; McNamara DB; Kadowitz PJ
J Appl Physiol (1985); 1987 May; 62(5):2066-74. PubMed ID: 2954941
[TBL] [Abstract][Full Text] [Related]
15. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
16. Reduction by arachidonic acid of prostaglandin I2-induced cyclic AMP formation. Involvement of prostaglandins E2 and F2 alpha.
Faili A; Randon J; Vargaftig BB; Hatmi M
Biochem Pharmacol; 1993 May; 45(9):1815-20. PubMed ID: 8388209
[TBL] [Abstract][Full Text] [Related]
17. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
18. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach.
Needleman P; Whitaker MO; Wyche A; Watters K; Sprecher H; Raz A
Prostaglandins; 1980 Jan; 19(1):165-81. PubMed ID: 6247744
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
Hornberger WB; Patscheke H
Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
[TBL] [Abstract][Full Text] [Related]
20. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.
Patscheke H
Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
